Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 4/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | CTSE | P14091 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434825 | 0.88 | HRH3 (0.40) | HRH3BACE1BACE2CTSDCTSE | |
| SCHEMBL6259042 | 0.88 | HRH3 (0.40) | HRH3BACE1BACE2CTSDCTSE | |
| SCHEMBL5152963 | 0.84 | GRIN1 (0.37) | BACE1GRIN1GRIN2B | |
| SCHEMBL6207720 | 0.83 | MEN1 (0.36) | HRH3BACE1BACE2CTSDCTSE | |
| SCHEMBL2431931 | 0.83 | MEN1 (0.36) | HRH3BACE1BACE2CTSDCTSE | |
| SCHEMBL5155645 | 0.73 | SMYD3 (0.32) | — | |
| SCHEMBL5360641 | 0.73 | SMYD3 (0.32) | — | |
| SCHEMBL25361349 | 0.72 | HRH3 (0.55) | HRH3KCNH2EPHX2 | |
| SCHEMBL3180030 | 0.72 | HRH3 (0.55) | HRH3KCNH2EPHX2 | |
| SCHEMBL7347162 | 0.72 | HRH3 (0.55) | HRH3KCNH2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | HRH3 1960/4885KCNH2 1485/4885BACE1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.